GlaxoSmithKline plc (LSE: GSK NYSE: GSK), often abbreviated to GSK, is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom. It is the world's third largest pharmaceutical company measured by revenues (after Johnson & Johnson and Pfizer). It has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions. It also has a large consumer healthcare division which produces and markets oral healthcare products, nutritional drinks and over-the-counter medicines, including Sensodyne, Horlicks and Gaviscon.
Campaign Finance$26,753,629 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of GlaxoSmithKline
Names of Lobbyists
Firm Hired Amount GlaxoSmithKline $65,475,000 Fleishman-Hillard Inc $0
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Fed Budget & Appropriations,
- Medical Research & Clin Labs,
- Foreign Relations,
- Government Issues
Most Frequently Disclosed Bills
Bill No. Title S.515 Patent Reform Act of 2009 H.R.3590 Service Members Home Ownership Tax Act of 2009 H.R.1260 Patent Reform Act of 2009 S.1145 Patent Reform Act of 2007 H.R.3200 America's Affordable Health Choices Act of 2009 S.610 Patent Reform Act of 2009 H.R.1908 Patent Reform Act of 2007 H.R.1548 Pathway for Biosimilars Act S.1679 Affordable Health Choices Act H.R.6331 Medicare Improvements for Patients and Providers Act of 2008
RegulationsMentioned in 581 dockets; Submitted to 87 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "GlaxoSmithKline" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for GlaxoSmithKline
- Toggle 5 FDA Treat Weight Loss Claims for Dietary Supplements as Disease Claims 2008
- Toggle 3 FDA FDA Transparency Task Force; Public Meeting 2009
- Toggle 2 FDA Draft Guidance for Industry on Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products; Availability 2009
- Toggle 2 FDA Remove metered-dose inhalers (MDI) containing the single active moieties beclomethasone, fluticasone, and salmeterol, respectively, from the essential-use list of ozone-depleting substance 2005
- Toggle 2 FDA Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs that are Regulated Under a Biologics License Application, and Animal Drugs 2005
- Toggle 2 FDA Request the Commissioner of Food and Drug, Pursuant to 21 C.F.R. 10.85, two Questions Regarding the Listing of Patents in the Orange Book, Whether Patents of the Following Kind Should be Listed in FDA's Publication Approved Drug Products With Therapeutic Equivalence Evaluations, Commonly Known as the Orange Book 2005
- Toggle 2 FDA Providing Effective Information to Consumers about Prescription Drug Risks and Benefits; Public Workshop 2009
- Toggle 2 FDA International Conference on Harmonisation; Draft Guidance on Q8(R1) Pharmaceutical Development 2007
- Toggle 1 FDA Guidance for Industry; Advisory Committee Meetings: Preparation and Public Availability of Information Given to Advisory Committee Members 2007
- Toggle 1 FDA Investigational New Drug Applications; Co-Development of Investigational Drugs 2010
Mentions in Document Text
View all mentions data for GlaxoSmithKline
- Toggle 484 FWS 90-Day Finding on a Petition To List All Chimpanzees (Pan troglodytes) as Endagered 2010
- Toggle 231 FDA Treat Weight Loss Claims for Dietary Supplements as Disease Claims 2008
- Toggle 29 FDA Generic Drug Speeches & Policy and Procedure Guides 1990
- Toggle 18 FDA Remove metered-dose inhalers (MDI) containing moiety albuter 2003
- Toggle 16 EPA National Emission Standards for Hazardous Air Pollutants: Final Standards for Hazardous Air Pollutants for Hazardous Waste Combustors (Phase I Final Replacement Standards and Phase II) 2004
- Toggle 12 FDA Specific Legal and Scientific Requirements be Upheld in the Review of Proposed Generic Copies of Inhalation Products Containing Fluticasone Propionate and/or Salmeterol Xinafoate 2009
- Toggle 11 FDA Agency Information Collection Activities; Proposed Collection; Comment Request; Healthcare Professional Survey of Prescription Drug Promotion 2012
- Toggle 11 NIH Recently Posted NIH Rules and Notices. Unknown
- Toggle 11 FDA Current Good Manufacturing Practice and Hazard Analysis and Risk-Based Preventive Controls For Human Food 2011
- Toggle 10 EPA Protection of Stratospheric Ozone: Allocation of Essential Use Allowances for Calendar Year 2006 2006
Federal Spending19 contracts
Federal grants, contracts and loans are reported by federal agencies using the FPDS and FAADS systems. The data is made available to the public at USASpending.gov. Please note that the completeness and quality of the data varies greatly by agency.
Only grants, contracts and loans with amounts over $1 million are shown.
Because company names are not reported in a standardized manner, we cannot reliably determine the company receiving the contract or award. The results shown here are based on a search for the company name. Individual records may be missed or erroneously included because of name variations. For more information, please see our federal spending methodology page.
Note: Company names in federal spending data are not standardized. The table below is included only as a sample of what is available in the data and has not been reviewed for accuracy or completeness. To investigate the data further, use the links at the bottom of the table.
|Glaxosmithkline Llc||2012||Centers For Disease Control||VACCCINE FOR CHILDREN 2012||$148,967,648|
|Glaxosmithkline Llc||2012||Centers For Disease Control||VACCCINE FOR CHILDREN 2012||$95,970,006|
|Glaxosmithkline Llc||2012||Centers For Disease Control||VACCCINE FOR CHILDREN 2012||$59,648,298|
|Glaxosmithkline Llc||2012||Centers For Disease Control||VACCCINE FOR CHILDREN 2012||$40,922,066|
|Glaxosmithkline Llc||2011||Office Of Assistant Secretary For Management And Budget||RESEARCH AND DEVELOPMENT FACILITIES||$38,506,842|
|Glaxosmithkline Llc||2012||Centers For Disease Control||PEDIATRIC FLU VACCINE||$13,673,350|
|Glaxosmithkline||2002||Centers For Disease Control||$11,750,000|
|Glaxosmithkline Llc||2012||Centers For Disease Control||2012 GSK ADULT VACCINES||$8,728,937|
|Glaxosmithkline Llc||2012||Centers For Disease Control||GSK 2011 VFA||$7,464,818|
Contractor Misconduct40 Instances
This information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.
More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.
|Misconduct Type||Hired By||Incident||Year||Disposition||Penalty|
|Health||None||2011 Criminal and Civil Investigations Settlement||2011||Settlement||$3,000,000,000|
|Health||None||Avandia Marketing, Sales Practices and Products Liability Litigation||2007||Settlement||$770,000,000|
|Health||None||Puerto Rico Drug Manufacturing Facility Settlement||2010||Pleaded Guilty||$750,000,000|
|Antitrust||None||Relafen Antitrust Litigation||2004||Settlement||$175,000,000|
|Defective Pricing||None||Zofran and Kytril False Claims Act Violations||2005||Settlement||$150,000,000|
|Antitrust||None||Augmentin Antitrust Litigation||2004||Settlement||$92,000,000|
|Antitrust||None||Relafen Consumer Litigation||2004||Settlement||$75,000,000|
|Antitrust||None||Average Wholesale Price (AWP) Drug Litigation||2002||Settlement||$70,000,000|
EPA Violations5 Enforcement Actions
Figures are based on data from the Environmental Protection Agency’s ECHO website. The ECHO database contains federal and state environmental enforcement actions. Data displayed here includes only those actions that began after 2000 and resulted in fines of over $1 million.
Actions where the company was the sole defendant are listed first. Actions where the company is one of multiple defendants are listed subsequently.
For more information see our EPA methodology page.
|Air Products & Chemical, Inc Et Al||Glaxosmithkline (+40 others)||2005||Elkton, Md||$24,500,000|
|3m Company||SmithKline Beecham Corporation (+106 others)||2008||Wood Ridge, Nj||$18,000,000|
|Agere Systems, Et Al||Smithkline Beecham Corp D/B/A Glaxosmithkline (+138 others)||2007||Elkton, Md||$11,300,000|
|3m Company Et Al.||SmithKline Beecham Corporation (+67 others)||2004||Carlstadt, Nj||$8,649,902|
|Abb, Inc.||SmithKline Beecham Corporation (+72 others)||2007||Wood Ridge, Nj||$1,400,000|
Advisory Committees15 people on 17 committees
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "GlaxoSmithKline" that sat on federal advisory committees.
- Toggle Department of Health and Human Services 10 people on 12 committees
- Toggle Environmental Protection Agency 3 people on 3 committees
- Toggle Department of State 1 person on 1 committee
- Toggle National Science Foundation 1 person on 1 committee